EXENATIDE PACKAGE INSERT PDF

These may be symptoms of thyroid cancer. Tell your healthcare provider if you take other diabetes medicines. Talk to your healthcare provider about managing low blood sugar. Signs and symptoms of low blood sugar include dizziness or lightheadedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery Kidney problems Tell your healthcare provider if you have or had kidney problems.

Author:Malar Zolozilkree
Country:Nepal
Language:English (Spanish)
Genre:Photos
Published (Last):9 July 2004
Pages:121
PDF File Size:17.62 Mb
ePub File Size:12.33 Mb
ISBN:462-8-22724-916-5
Downloads:40412
Price:Free* [*Free Regsitration Required]
Uploader:Kirg



Serious bleeding, which may be fatal, from drug induced immune mediated thrombocytopenia has been reported with exenatide use [see Warnings and Precautions 5. Pen-sharing poses a risk for transmission of blood-borne pathogens. After initiation of BYETTA, and after dose increases, observe patients carefully for signs and symptoms of pancreatitis including persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting.

Therefore, patients receiving BYETTA and a sulfonylurea may require a lower dose of the sulfonylurea to reduce the risk of hypoglycemia.

In patients at increased risk of hypoglycemia consider reducing the dose of insulin [see Adverse Reactions 6. For additional information on glucose-dependent effects see Mechanism of Action Some of these events occurred in patients receiving one or more pharmacologic agents known to affect renal function or hydration status, such as angiotensin converting enzyme inhibitors, nonsteroidal anti-inflammatory drugs, or diuretics. Some events occurred in patients who had been experiencing nausea, vomiting, or diarrhea, with or without dehydration.

Reversibility of altered renal function has been observed in many cases with supportive treatment and discontinuation of potentially causative agents, including BYETTA. Exenatide has not been found to be directly nephrotoxic in preclinical or clinical studies.

If there is worsening glycemic control or failure to achieve targeted glycemic control, alternative antidiabetic therapy should be considered [see Adverse Reactions 6. If a hypersensitivity reaction occurs, the patient should discontinue BYETTA and other suspect medications and promptly seek medical advice. Inform and closely monitor patients with a history of anaphylaxis or angioedema with another GLP 1 receptor agonist for allergic reactions, because it is unknown whether such patients will be predisposed to anaphylaxis with BYETTA [see Adverse Reactions 6.

Drug-induced thrombocytopenia is an immune mediated reaction, with exenatide-dependent anti platelet antibodies. In the presence of exenatide, these antibodies cause platelet destruction.

EMPLOYEE RELATIONS WYNTER DANIELS PDF

BYETTA PACKAGE INSERT PDF DOWNLOAD

Volabar Exenatide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Careful monitoring of blood glucose is recommended. Let the autoinjector come to room temperature for approximately 15 minutes before administration. The ijsert is not indicated in infants or neonates. The concurrent use of exenatide with prandial insulin has not been studied.

BITSCH TRUMPET ETUDES PDF

Email your Doctor Discussion Guide

Serious bleeding, which may be fatal, from drug induced immune mediated thrombocytopenia has been reported with exenatide use [see Warnings and Precautions 5. Pen-sharing poses a risk for transmission of blood-borne pathogens. After initiation of BYETTA, and after dose increases, observe patients carefully for signs and symptoms of pancreatitis including persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting. Therefore, patients receiving BYETTA and a sulfonylurea may require a lower dose of the sulfonylurea to reduce the risk of hypoglycemia. In patients at increased risk of hypoglycemia consider reducing the dose of insulin [see Adverse Reactions 6.

Related Articles